La cadena de opciones muestra datos clave de las opciones de acciones de Traws Pharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Traws Pharma..

Traws Pharma (NASDAQ:TRAW) Bolsa, Cadena de Opciones

Traws Pharma

Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.

Konskie,,Poland,-,March,08,,2025:,Restoration,Hardware,Company,Logo

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADBE

BIAF

CGBS

EONR

FGEN

GNLN

HCTI

HUSA

INDO

NINE

PRZO

RNTX

RSLS

SBET

TPET

TRAW

USEG

VEON

RH sorprende con ganancias positivas en el primer trimestre y mantiene su guía para 2025, mientras sus acciones suben un 18,2 %.

Las acciones de RH se disparan un 18%; Aquí están 20 acciones que se mueven antes de la apertura del mercado

ARQT

ATPC

BDTX

DRCT

GCTK

ITCI

LAES

LDTC

QBTS

QMMM

RGTI

RIME

SAGE

STAI

VMAR

Sage Therapeutics sube 34% tras oferta de Biogen. Conoce los mayores ganadores y perdedores del premercado de EE.UU.

Las acciones de Sage Therapeutics (SAGE) se disparan un 34%; 20 acciones que se mueven en premercado

Traws Pharma Inc

TraWell Co SpA

Press Releases

Traws Pharma Announces Management Updates

Earnings

Traws Pharma Reports Full Year 2024 Results and Business Highlights

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

Health Care

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

MAG 8 Momentum: NIVF, TRAW, KPRX, PNPN.V Lead $3 Undercard Surge – More Stocks Inside!

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

EYEN

IKNA

IOVA

KPRX

NIVF

PNPNF

PRSO

SNYR

TSXV:PNPN

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Artelo Biosciences

Biofrontera

Clearmind Medicine

China Pharma Holding

Evoke Pharma

Gelteq

Impact BioMedical

IM Cannabis

InMed Pharmaceuticals Inc. - Common Shares

InMed Pharmaceuticals

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lyra Therapeutics

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

PainReform

ProPhase Labs

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

Talphera

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

VYNE Therapeutics

XORTX Therapeutics

cbdMD

Comments

Traws Pharma

Traws Pharma (TRAW) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL